MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$3,583,221
EPS
-$0.07
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Grant revenue
-
-
3,337
1,848
Research and development
2,462,042
1,611,167
1,008,839
1,638,917
General and administrative
1,570,138
1,819,245
1,637,591
1,480,319
Total operating expenses
4,032,180
3,430,412
2,646,430
3,119,236
Loss from operations
-4,032,180
-3,430,412
-2,643,093
-3,117,388
Interest income
358,923
134,784
118,664
150,669
Other income
79,000
-
77,500
-
Foreign currency gain (loss)
2,953
7,711
-8,701
-5,691
Total other income
440,876
142,495
187,463
144,978
Net loss
-3,591,304
-3,287,917
-2,455,630
-2,972,410
Foreign currency translation
8,083
9,014
-5,180
-1,117
Total comprehensive loss
-3,583,221
-3,278,903
-2,460,810
-2,973,527
Basic EPS
-0.07
-0.22
-0.319
-0.47
Diluted EPS
-0.07
-0.22
-0.319
-0.47
Basic Average Shares
53,483,504
14,685,448
7,704,755
6,372,938
Diluted Average Shares
53,483,504
14,685,448
7,704,755
6,372,938
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$3,583,221
(-10.57%↓ Y/Y)
Foreign currency
translation
$8,083
(580.84%↑ Y/Y)
Interest income
$358,923
(101.61%↑ Y/Y)
Other income
$79,000
Foreign currency gain
(loss)
$2,953
(110.14%↑ Y/Y)
Net loss
-$3,591,304
(-10.88%↓ Y/Y)
Total other income
$440,876
(196.08%↑ Y/Y)
Loss from operations
-$4,032,180
(-19.02%↓ Y/Y)
Total operating
expenses
$4,032,180
(15.01%↑ Y/Y)
Research and development
$2,462,042
(28.75%↑ Y/Y)
General and
administrative
$1,570,138
(-1.48%↓ Y/Y)
Buy us a coffee
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)